Telomere Length Prognostic in Hepatocellular Carcinoma

This article originally appeared here.
Share this content:
Telomere Length Prognostic in Hepatocellular Carcinoma
Telomere Length Prognostic in Hepatocellular Carcinoma

THURSDAY, Aug. 24, 2017 (HealthDay News) -- Telomere attrition occurs in tumor cells from patients with hepatocellular carcinoma (HCC), and shortened telomeres are independent prognosticators for HCC patients, according to a study published online Aug. 21 in the Journal of Pathology.

Li-Jie Ma, from Fudan University in Shanghai, and colleagues used telomere-specific fluorescence in situ hybridization and quantitative polymerase chain reaction to assess telomere length in HCC cell lines, tumor tissues, and nontumor cells within the tumor.

The researchers found that, compared with their normal counterparts, significant telomere attrition was found in tumor cells and cancer-associated fibroblasts (CAFs), but not in intratumor leukocytes or bile duct epithelial cells. On tissue microarrays of 257 surgically treated HCC patients, reduced intensity of telomere signals in tumor cells or CAFs were associated with larger tumor size and presence of vascular invasion (P < 0.05). There was a correlation for shortened telomeres in tumor cells or CAFs with reduced survival and increased recurrence, and they were independently prognostic for HCC patients (P < 0.05). The findings were validated in a cohort of 371 HCC patients from The Cancer Genome Atlas database. There was a correlation for telomerase reverse transcriptase promoter mutation with telomere shortening in HCC.

"Telomere variation in tumor cells and non-tumor cells within the tumor microenvironment of HCC was a valuable prognostic biomarker for this fatal malignancy," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »